NMOSD(50) | HC (30) | P | |
---|---|---|---|
Gender, n (% female) | 48(98%) | 27(90%) | 0.358 |
Age at sampling, years | 46.46 ± 15.04 | 51.30 ± 12.71 | 0.144 |
Age at onset, years | 41.9 ± 15.71 | – | – |
Follow-up duration, years | 4.66 ± 4.33 | – | – |
Annualized relapse rate (ARR) | 2.24 ± 0.97 | – | – |
EDSS at nadir | 3.98 ± 2.12 | – | – |
Presentation at sampling, n (%) | |||
ON | 7(14%) | – | – |
Area postrema syndrome | 2(4%) | – | – |
AM | 26(52%) | – | – |
Brain stem syndrome | 6(12%) | – | – |
Diencephalic clinical syndrome | 3(6%) | – | – |
Cerebral syndrome | 6(12%) | – | – |
length of newly identified spinal cord lesion (vertebral segments) | 5(1, 15) | – | – |
AQP4-Ab, n (%) | 28(56%) | – | – |
Imunossupressive agents and dosage, n (%) | |||
Prednisonlone (12 mg/d) | 5(10%) | – | – |
Azathioprine (2 mg/kg.d) | 8(16%) | – | – |
Mycophenolate Mofetil(1.5 g/d) | 7(14%) | – | – |
Rituximaba | 30(60%) | – | – |